Characteristics of late-onset myasthenia gravis

Journal of Neurology

Volumn 259, Issue 10, 2012, Pages 2167-2171

  Živković, Saša A ^a,b   Clemens, Paula R ^a,b   Lacomis, David ^b,c  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Elderly; Myasthenia gravis; Myasthenic crisis; Ocular myasthenia; Seropositive myasthenia

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL FEATURE; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL;

AGE OF ONSET; AGED; AUTOANTIBODIES; AUTOANTIGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES;

EID: 84867332830     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6478-6     Document Type: Article

References (30)

1. Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475-490
2. Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM (2003) Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 74:1105-1108
3. Aragones JM, Bolibar I, Bonfill X, Bufill E, Mummany A, Alonso F et al (2003) Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 60:1024-1026
4. Aarli JA (2008) Myasthenia gravis in the elderly: is it different? Ann NY Acad Sci 1132:238-243
5. Phillips LH 2nd, Torner JC (1996) Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 47:1233-1238
6. Guptill JT, Sanders DB, Evoli A (2011) Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 44:36-40
7. Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP (1990) The relationship of age to outcome in myasthenia gravis. Neurology 40:786-790
8. Phillips LH 2nd, Torner JC, Anderson MS, Cox GM (1992) The epidemiology of myasthenia gravis in central and western Virginia. Neurology 42:1888-1893
9. Schon F, Drayson M, Thompson RA (1996) Myasthenia gravis and elderly people. Age Ageing 25:56-58
10. Slesak G, Melms A, Gerneth F, Sommer N, Weissert R, Dichgans J (1998) Late-onset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60. Ann NY Acad Sci 841:777-780
11. Aarli JA (1999) Late-onset myasthenia gravis: a changing scene. Arch Neurol 56:25-27
12. Somnier FE (2005) Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 65:928-930
13. Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37:141-149
14. Aguiar Ade A, Carvalho AF, Costa CM, Fernandes JM, D'Almeida JA, Furtado LE et al (2010) Myasthenia gravis in Ceara, Brazil: clinical and epidemiological aspects. Arq Neuropsiquiatr 68:843-848
15. Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P et al (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann NY Acad Sci 998:413-423
16. Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H et al (2011) Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 305:97-102
17. Singhal BS, Bhatia NS, Umesh T, Menon S (2008) Myasthenia gravis: a study from India. Neurol India 56:352-355
18. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72:1548-1554
19. AAEM Quality Assurance Committee (2001) Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve 24:1236-1238
20. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM et al (2006) Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 29:1263-1268
21. Phillips LH 2nd, Juel VC (1999) Myasthenia gravis in the tenth decade. Muscle Nerve 22:1297-1298
22. Zhang X, Yang M, Xu J, Zhang M, Lang B, Wang W et al (2007) Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry 78:386-390
23. Shinomiya N, Nomura Y, Segawa M (2004) A variant of childhood-onset myasthenia gravis: HLA typing and clinical characteristics in Japan. Clin Immunol 110:154-158
24. Stacy S, Williams EL, Standifer NE, Pasquali A, Krolick KA, Infante AJ et al (2010) Maintenance of immune tolerance to a neo-self acetylcholine receptor antigen with aging: implications for late-onset autoimmunity. J Immunol 184:6067-6075
25. Symmons DP (2002) Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 16:707-722
26. US Census Bureau (2011) Census 2009: Quickfacts. http://quickfacts. census.gov/qfd/states/42000.html. Accessed on 29 Sept 2011
27. Kuypers DR (2009) Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging 26:715-737
28. Basic-Jukic N, Brunetta B, Kes P (2010) Plasma exchange in elderly patients. Ther Apher Dial 14:161-165
29. Caress JB, Kennedy BL, Eickman KD (2010) Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf 9:971-979
30. Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I et al (1997) Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48:1253-1260